Guided lymph node removal after chemo-immunotherapy for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether removing lymph nodes based on a special imaging technique (called TDLN) is better for people with esophageal cancer who had chemo-immunotherapy before surgery. It aims to improve surgery results and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to be in generally good health (able to do light activities without needing rest often).
- You must have a specific type of esophageal cancer called squamous cell carcinoma.
- You must have already received a combination of chemotherapy and immunotherapy to shrink the tumor before surgery.
- Your cancer should be considered removable by surgery (no spread to distant organs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
This study tests whether giving additional immunotherapy after esophageal cancer surgery can help prevent the cancer from coming back. If you've already had chemotherapy and immunotherapy before surgery, this trial may offer a way to continue that benefit after your operation.
This trial studies whether adding chemotherapy after surgery for esophageal squamous cell cancer can reduce the chance the cancer returns. It focuses on people whose surgery removed cancerous lymph nodes and who are healthy enough to tolerate chemotherapy.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.